MicroRNAs: a new key in lung cancer Yunlong ZhangQian YangSiwang Wang Review Article 19 August 2014 Pages: 1105 - 1111
Phase I study of cabazitaxel plus cisplatin in patients with advanced solid tumors: study to evaluate the impact of cytochrome P450 3A inhibitors (aprepitant, ketoconazole) or inducers (rifampin) on the pharmacokinetics of cabazitaxel John SarantopoulosAlain C. MitaA. Craig Lockhart Original Article 12 October 2014 Pages: 1113 - 1124
Nonclinical pharmacokinetics and activity of etirinotecan pegol (NKTR-102), a long-acting topoisomerase 1 inhibitor, in multiple cancer models Ute HochCarl-Michael StaschenMichael A. Eldon Original Article Open access 17 September 2014 Pages: 1125 - 1137
Docetaxel, cisplatin, and fluorouracil combination in neoadjuvant setting in the treatment of locally advanced gastric adenocarcinoma: Phase II NEOTAX study Nuriye OzdemirHuseyin AbaliNurullah Zengin Original Article 19 September 2014 Pages: 1139 - 1147
Phase II trial of carboplatin and pemetrexed as first-line chemotherapy for non-squamous non-small cell lung cancer, and correlation between the efficacy/toxicity and genetic polymorphisms associated with pemetrexed metabolism: Hokkaido Lung Cancer Clinical Study Group Trial (HOT) 0902 Kenya KanazawaHiroshi YokouchiHokkaido Lung Cancer Clinical Study Group Original Article 08 October 2014 Pages: 1149 - 1157
The safety and efficacy of paclitaxel and carboplatin with or without bevacizumab for treating patients with advanced nonsquamous non-small cell lung cancer with interstitial lung disease Ryoko ShimizuDaichi FujimotoKeisuke Tomii Original Article 23 September 2014 Pages: 1159 - 1166
Folate levels measured by LC–MS/MS in patients with colorectal cancer treated with different leucovorin dosages Helena TaflinYvonne WettergrenKristoffer Derwinger Original Article Open access 20 September 2014 Pages: 1167 - 1174
Effects of combined treatment of α-tocopherol, l-ascorbic acid, selenium and zinc on bleomycin, etoposide and cisplatin-induced alterations in testosterone synthesis pathway in rats Narayana Kilarkaje Original Article 19 September 2014 Pages: 1175 - 1189
Phase I dose escalation and pharmacokinetic study of oral gefitinib and irinotecan in children with refractory solid tumors R. C. BrennanW. FurmanL. M. McGregor Original Article 26 September 2014 Pages: 1191 - 1198
Phase II study of adjuvant vinorelbine and cisplatin in Japanese patients with completely resected stage II and III non-small cell lung cancer Makoto SonobeKen-ichi OkuboHiroshi Date Original Article 25 September 2014 Pages: 1199 - 1206
A retrospective study of docetaxel or paclitaxel in patients with advanced or recurrent esophageal squamous cell carcinoma who previously received fluoropyrimidine- and platinum-based chemotherapy Tsuyoshi ShirakawaKen KatoYasuhiro Shimada Original Article 30 September 2014 Pages: 1207 - 1215
Effect of front-line chemotherapy on circulating CK-19 mRNA-positive cells in patients with metastatic breast cancer V. GeorgouliasS. ApostolakiD. Mavroudis Original Article 26 October 2014 Pages: 1217 - 1225
Phase I clinical trial of temsirolimus and vinorelbine in advanced solid tumors Caroline I. PiatekGrace L. RajaAgustin A. Garcia Original Article 06 November 2014 Pages: 1227 - 1234
Risk factors for 6-month continuation of S-1 adjuvant chemotherapy for resected pancreatic cancer Toru AoyamaYusuke KatayamaSoichiro Morinaga Original Article 09 October 2014 Pages: 1235 - 1240
Phase I study of intravenously administered ATI-1123, a liposomal docetaxel formulation in patients with advanced solid tumors Devalingam MahalingamJohn J. NemunaitisAlain C. Mita Original Article 11 October 2014 Pages: 1241 - 1250
Trastuzumab, in combination with carboplatin and docetaxel, does not prolong the QT interval of patients with HER2-positive metastatic or locally advanced inoperable solid tumors: results from a phase Ib study Na XuCharles H. RedfernCaroline Trudeau Original Article Open access 26 October 2014 Pages: 1251 - 1260
A Phase II trial of axitinib in patients with various histologic subtypes of advanced thyroid cancer: long-term outcomes and pharmacokinetic/pharmacodynamic analyses E. E. W. CohenM. TortoriciP. Bycott Original Article Open access 15 October 2014 Pages: 1261 - 1270
Pharmacokinetics of endoxifen and tamoxifen in female mice: implications for comparative in vivo activity studies Joel M. ReidMatthew P. GoetzMatthew M. Ames Original Article 16 October 2014 Pages: 1271 - 1278
Pharmacokinetics of single-agent axitinib across multiple solid tumor types Michael A. TortoriciEzra E. W. CohenJohn P. Fruehauf Original Article 22 October 2014 Pages: 1279 - 1289
Treatment outcomes of gemcitabine alone versus gemcitabine plus platinum for advanced biliary tract cancer: a Korean Cancer Study Group retrospective analysis In Gyu HwangHong Suk SongJoung-Soon Jang Original Article 18 October 2014 Pages: 1291 - 1296
Addition of bevacizumab enhances antitumor activity of erlotinib against non-small cell lung cancer xenografts depending on VEGF expression Heyan LiKoichi TakayamaYoichi Nakanishi Original Article Open access 26 October 2014 Pages: 1297 - 1305
Clinical usefulness of therapeutic concentration monitoring for imatinib dosage individualization: results from a randomized controlled trial V. GottaN. WidmerT. Buclin Clinical Trial Report 09 October 2014 Pages: 1307 - 1319
Safety and pharmacokinetics of S-1 in a recurrent colon cancer patient with chronic myeloid leukemia treated with dasatinib: a case report Toshinori SuedaToshihiro KudoTaroh Satoh Short Communication 06 November 2014 Pages: 1321 - 1324
